Speaker illustration

Professor Jean-Luc Vachiery

Erasme Academic Hospital, Brussels (Belgium)

Member of:

European Society of Cardiology
Heart Failure Association

Jean-Luc Vachiéry is Clinical Professor of Cardiology and Director of the Pulmonary Vascular Diseases and heart Failure Clinic (since 2008) at the Hôpital Erasme, at he Free University of Brussels. JL has authored several manuscripts on pulmonary vascular disorders (H-index 51) and is section editor for the Journal of heart and lung transplantation. JL has been active in several scientific societies, with leadership positions. At the ESC, JL chaired the Working Group on Pulmonary Circulation and Right Ventricular Function (2006 – 2008), was member of the Nucleus until 2020 and now member-at-large. He was a Task Force member and section editor of the European Guidelines on pulmonary Hypertension (2009, 2015 and 2022). JL is fluent in French and english, can handle dutch and understands Italian. He is a determined football fan (Paris St Germain and Union St Gilloise) and rugby addict. In his spare time, he loves reading, cooking and caring of his loved ones.

Current treatment of pulmonary hypertension: it is all about vasodilators

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session type: Moderated ePosters

Thumbnail

Improving long-term outcomes in Pulmonary Arterial Hypertension: time matters!

Event: ESC Congress 2021 - The Digital Experience

Topic: Pulmonary Hypertension

Session type: Satellite Symposium

Thumbnail

Evolving combination strategies in pulmonary arterial hypertension: one year after the 6th World Symposium of Pulmonary Hypertension

Event: ESC Congress 2019

Topic: Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure

Session type: Satellite Symposium

Thumbnail

Initial combination therapy in pulmonary arterial hypertension: a new standard of care?

Event: ESC Congress 2018

Topic: Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure

Session type: Satellite Symposium

Thumbnail

Can you achieve more for your pulmonary arterial hypertension (PAH) patients? An expert review of key recent data with initial combination therapy

Event: ESC Congress 2017

Topic: Chronic pulmonary hypertension

Session type: Satellite Symposium

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb